Restoration, Not Bypass: Otoferlin Gene Therapy and a New Era in Hearing Loss Treatment

The FDA approval of Otarmeni, an AAV-based gene therapy for biallelic OTOF-associated sensorineural hearing loss, represents a conceptual shift in otology: from bypassing defective auditory physiology to restoring it. Unlike cochlear implantation, which circumvents damaged sensory structures, OTOF gene replacement targets a synaptic deficit in a structurally intact cochlea....

Audiologists should be aware that FDA-approved otoferlin gene therapy (Otarmeni) is now a biological treatment option for patients with confirmed biallelic OTOF-associated SNHL; refer eligible patients to specialized otolaryngology or gene therapy centers for evaluation.

The FDA approval of the first AAV-based gene therapy for hereditary hearing loss marks a fundamental philosophical shift in treatment—from sensory bypass to biological restoration—with potential to reshape the care pathway for genetic hearing loss.

1. 01FDA has approved Otarmeni, an AAV-based gene therapy, for biallelic OTOF-associated sensorineural hearing loss.
2. 02The therapy targets the underlying otoferlin protein deficiency rather than compensating for hair-cell dysfunction.
3. 03This represents a conceptual shift from auditory bypass (hearing aids, cochlear implants) to biological restoration.
4. 04OTOF-associated hearing loss accounts for a subset of congenital profound SNHL; genetic confirmation is required for eligibility.
5. 05The editorial frames this approval as the opening of a new era in hearing loss treatment.

PMID

42470357

DOI

10.1002/ohn.70347.

Journal

Otolaryngology–Head and Neck Surgery

Publication type

editorial

Evidence level

5

Population

Patients with biallelic OTOF-associated sensorineural hearing loss

Intervention

AAV-based otoferlin gene therapy (Otarmeni)

Comparator

Cochlear implants and hearing aids (conceptual comparison)